Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Eating Habits and Behavior in People Affected by Lipodystrophy: Observational Study (lipo-diet_2024)

11 de noviembre de 2026 actualizado por: IRCCS Azienda Ospedaliero-Universitaria di Bologna

Title: Dietary Habits and Eating Behavior in People with Lipodystrophy: An Observational Study.

Purpose: The purpose of this study is to investigate and analyze the dietary habits and eating behaviors of patients diagnosed with lipodystrophy. Since there is currently a lack of specific data on how these patients approach nutrition, this research aims to provide essential information to improve nutritional guidelines. Additionally, the study seeks to understand if there is a relationship between eating behaviors and the patients' clinical data, such as blood test results and body measurements (anthropometric parameters).

Study Design:

This is an observational, cross-sectional, single-center study with a 2-year enrollment period. Participants will be recruited during their regular medical visits at the Endocrinology Unit of the IRCCS AOU di Bologna, Policlinico Sant'Orsola.

During the study, the following activities will take place:

Clinical Data Collection: Researchers will record body measurements and blood test results as part of standard clinical practice.

Questionnaires: Patients will be asked to complete four specific questionnaires (available in Italian and English) regarding their food frequency, eating behavior patterns, tendencies toward orthorexia, and physical activity levels.

Format: These questionnaires can be completed electronically via a RedCap link (taking approximately 20-30 minutes) or on paper.

Eligibility:

Inclusion Criteria: Adults (18 years or older) with a confirmed diagnosis of lipodystrophy who provide informed consent.

Exclusion Criteria: Patients with HIV-related lipodystrophy or those who cannot understand the languages in which the questionnaires are provided.

Duration and Participation:

The study will last a total of 2 years and 6 months. The first 2 years are dedicated to patient selection and recruitment, followed by 6 months for data analysis. The researchers aim to enroll 30 participants.

Descripción general del estudio

Estado

Reclutamiento

Condiciones

Descripción detallada

1. Background and RationaleLipodystrophy refers to a rare and heterogeneous group of syndromes characterized by the total or partial loss of subcutaneous adipose tissue. This condition leads to severe metabolic complications, such as marked insulin resistance, early-onset diabetes, severe hypertriglyceridemia, and hepatic steatosis (fatty liver).A key factor in this pathology is hypoleptinemia (deficiency of the hormone leptin), which plays a crucial role in regulating energy balance. The lack of leptin disrupts satiety signals, often resulting in hyperphagia (insatiable hunger), with energy intake potentially exceeding requirements by up to 40%. While lifestyle and dietary modifications are considered the "cornerstone" of treatment, there is currently a significant lack of structured data and evidence-based nutritional guidelines for these patients.2. Study ObjectivesPrimary Objective: To identify, analyze, and describe the lifestyle of patients with a focus on dietary habits, eating behaviors, and physical activity.Secondary Objective: To explore the relationship between these behaviors and clinical data, including anthropometric measurements and biochemical (blood) parameters.3. Study Population and EligibilityThe study aims to enroll 30 patients managed at the Endocrinology Unit of the IRCCS AOU di Bologna, Policlinico Sant'Orsola.Inclusion Criteria: Male and female adults (≥ 18 years old) with a confirmed diagnosis of lipodystrophy who provide written informed consent.Exclusion Criteria: Patients with HIV-related lipodystrophy or those unable to understand the languages in which the questionnaires are provided.4. Study Design and MethodologyThis is a prospective, cross-sectional, observational, single-center study. Data will be collected during routine endocrinological visits through the following means:A. Clinical and Biochemical ParametersAnthropometric Data: Weight, height, BMI, waist and hip circumference, and body fat percentage.Biochemical Data: Fasting plasma glucose, HbA1c, full lipid profile (total cholesterol, HDL, LDL, triglycerides), liver enzymes (AST, ALT), kidney function, insulin levels, and HOMA-IR.B. Self-Assessment QuestionnairesParticipants will complete four validated tools (estimated time: 30 minutes, via RedCap or paper):Food Frequency Questionnaire (FFQ): To assess the intake frequency of 36 food items over the past 12 months.Three-Factor Eating Questionnaire (TFEQ-R18): To evaluate cognitive restraint, uncontrolled eating, and emotional eating.Teruel Orthorexia Scale (TOS): To measure orthorexic tendencies (obsession with healthy eating) in both "healthy" and "nervosa" dimensions.IPAQ-Short Form: To categorize physical activity levels as low, moderate, or high.5. Study Duration and AnalysisThe total study duration is 2 years and 6 months. This includes 2 years for patient recruitment and 6 months for data analysis. Statistical analysis will be performed using STATA 19 SE, comparing the observed dietary data with the 2024 LARN guidelines (Nutrient and Energy Reference Intake Levels) to identify deviations and correlations with metabolic health.

Tipo de estudio

De observación

Inscripción (Estimado)

30

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Ubicaciones de estudio

    • Bologna
      • Bologna, Bologna, Italia, 40138
        • Reclutamiento
        • IRCSS Azienda Ospedaliero-Universitaria di Bologna

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

N/A

Géneros elegibles para el estudio

Todos

Método de muestreo

Muestra no probabilística

Población de estudio

Male and female patients over the age of 18 attending the outpatient service of the Endocrinology and Diabetes Prevention and Treatment Unit - U. Pagotto - IRCCS AOU in Bologna, Policlinico Sant'Orsola - Malpighi during their visit to the dedicated clinic.

Descripción

Inclusion Criteria:

  • Obtaining informed consent
  • Age 18 or older at the time of diagnosis
  • Diagnosis of lipodystrophy

Exclusion Criteria:

  • Failure to understand the language in which the questionnaires are administered
  • HIV-related lipodystrophy

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Modelos observacionales: COHORT
  • Perspectivas temporales: PROSPECTIVE

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Food Frequency Questionnaire (FFQ)
Periodo de tiempo: baseline
baseline
Three-Factor Eating Questionnaire R-18 (TFEQ-R18)
Periodo de tiempo: baseline

Assessment of eating behavior using the 18-item validated questionnaire, evaluating three subscales: Cognitive Restraint (CR), Uncontrolled Eating (UE), and Emotional Eating (EE). Items are scored on a 4-point scale and converted to a 0-100 scale per domain, where higher scores indicate higher expression of the specific behavior.

baseline
Teruel Orthorexia Scale (TOS)
Periodo de tiempo: baseline
baseline
International Physical Activity Questionnaire - Short Form (IPAQ-Short Form)
Periodo de tiempo: baseline
baseline

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Body Mass Index (BMI)
Periodo de tiempo: baseline

Assessment of body weight status using BMI, calculated as weight in kilograms divided by height in meters squared (kg/m2).

baseline
Body Fat Percentage
Periodo de tiempo: baseline

Evaluation of total body fat composition measured via anthropometric assessment/bioelectrical impedance analysis (BIA).

baseline
Waist-to-Hip Ratio (WHR)
Periodo de tiempo: baseline

Assessment of abdominal obesity calculated as waist circumference divided by hip circumference.

baseline
Fasting Blood Glucose
Periodo de tiempo: baseline

Laboratory evaluation of serum/plasma fasting glucose concentration (mg/dL).

baseline
Glycated Hemoglobin (HbA1c)
Periodo de tiempo: baseline

Laboratory evaluation of glycated hemoglobin level (mmol/mol).

baseline
Fasting Serum Insulin
Periodo de tiempo: baseline

Laboratory evaluation of basal insulin levels micromol/mL.

baseline
Homeostatic Model Assessment for Insulin Resistance (HOMA-IR)
Periodo de tiempo: baseline

index score

baseline
Lipid Profile Parameters
Periodo de tiempo: baseline
baseline

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

30 de septiembre de 2025

Finalización primaria (Estimado)

30 de septiembre de 2027

Finalización del estudio (Estimado)

31 de marzo de 2028

Fechas de registro del estudio

Enviado por primera vez

4 de marzo de 2026

Primero enviado que cumplió con los criterios de control de calidad

11 de noviembre de 2026

Publicado por primera vez (Actual)

16 de noviembre de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

16 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

11 de noviembre de 2026

Última verificación

1 de marzo de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • lipo-diet_2024

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .